🌅 Good Morning! Here is your latest news update.
With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.
Watch LiveBritish Broadcasting CorporationHomeNewsSportBusinessTechnologyHealthCultureArtsTravelEarthAudioVideoLiveDocumentariesHomeNewsUS & CanadaUKUK PoliticsEnglandN. IrelandN. Ireland PoliticsScotlandScotland PoliticsWalesWales PoliticsAfricaAsiaChinaIndiaAustraliaEuropeLatin AmericaMiddle EastIn PicturesBBC InDepthBBC VerifySportBusinessWorld of BusinessTechnology of BusinessNYSE Opening BellTechnologyWatch DocumentariesArtificial IntelligenceAI v the MindHealthWatch DocumentariesCultureWatch DocumentariesFilm & TVMusicArt & DesignStyleBooksEntertainment NewsArtsWatch DocumentariesArts in MotionTravelWatch DocumentariesDestinationsAfricaAntarcticaAsiaAustralia and PacificCaribbean & BermudaCentral AmericaEuropeMiddle EastNorth AmericaSouth AmericaWorld’s TableCulture & ExperiencesAdventuresThe SpeciaListEarthWatch DocumentariesScienceNatural WondersClimate SolutionsSustainable BusinessGreen LivingAudioPodcast CategoriesRadioAudio FAQsVideoWatch DocumentariesBBC MaestroDiscover the WorldLiveLive NewsLive SportDocumentariesHomeNewsSportBusinessTechnologyHealthCultureArtsTravelEarthAudioVideoLiveDocumentariesWeatherNewslettersWatch LiveIndia's cheap weight-loss drugs could reshape global obesity fight9 hours agoShareSaveSoutik BiswasIndia correspondentShareSaveBloomberg via Getty ImagesWegovy launched in India in 2025, but the patent on its core ingredient expires in the country this weekIndia could soon get a lot thinner - at least in theory.
On Friday the patent on semaglutide - the molecule behind Danish drugmaker Novo Nordisk's blockbuster weight-loss drugs Wegovy and Ozempic - expires in the country.
This will allow domestic pharmaceutical companies to release cheaper copies or generics, triggering a rush of competition that could slash prices by more than half and rapidly expand access for people in India, and eventually in other countries too.
Investment bank Jefferies has called it a potential "magic-pill moment" for India, predicting the semaglutide market could eventually reach $1bn domestically with the right pricing and uptake.
Analysts expect around 50 branded semaglutide generics to enter the market within months - a familiar pattern in India's fiercely competitive pharmaceutical industry. When the diabetes drug sitagliptin went off patent in 2022, about 30 branded versions appeared within a month and nearly 100 within a year.
India's pharmaceutical industry, currently worth about $60bn, is expected to double by 2030. Much of it is built on generics - a manufacturing muscle that now sets the stage for fierce competition over semaglutide. What has until now been an expensive injection largely confined to affluent patients could soon become far more common.
Originally developed to treat diabetes, these drugs are now being hailed as game changers for weight loss, offering results that few previous treatments could match. Semaglutide belongs to a class of medicines known as GLP-1 receptor agonists, which mimic a hormone that regulates appetite and blood sugar.
By boosting insulin release and slowing the emptying of the stomach, the drugs make people feel full sooner and stay full longer. Originally developed for diabetes, they have become some of the most sought-after weight-loss treatments in the world.
Several Indian drugmakers are already preparing to make the move. According to Sheetal Sapale, vice-president at research firm Pharmarack, major firms including Cipla
0 Comments